John V Schloss
John V Schloss has spanned professional and cultural boundaries across a diverse range of research, educational, and business activities. His accomplishments include: discovery and development of new drugs and drug-delivery systems; authoring or co-authoring issued patents covering composition of matter and use of novel drug substances; extensive managerial experience in industry and academics (Chief Executive Officer, Research Supervisor, Director, and five times as Chair of an academic department); securing major competitive research awards from the NIH, Office of Naval Research, US-Israel Binational Science Foundation, Maine Technology Institute, and the Pfeiffer Research Foundation as Principal Investigator; and obtaining funding for, building, and managing core facilities for protein sequencing and amino acid analysis, large-scale fermentation, large-scale protein purification; and mass spectrometry.
links
https://www.researchgate.net/profile/John_Schloss2/publications
https://www.facebook.com/john.v.schloss
jschloss@une.edu
https://www.linkedin.com/in/john-schloss-4b381112
Research Interest
Epigenetic effects of nutraceuticals; The effect of nutraceuticals on drug pharmacometrics; Biomarkers of oxidative stress, with special emphasis on the transsulfuration pathway; Taurine and taurine metabolites; Glutathione.John V. Schloss was born in St. Louis and grew up in the Midwest (Missouri, Kansas, and Oklahoma). He obtained a B.S. in chemistry and biology from the University of Tulsa in 1973 and a Ph.D. in biomedical sciences from the University of Tennessee-Oak Ridge Graduate School of Biomedical Sciences, located within the Biology Division of Oak Ridge National Laboratory, in 1978. After conducting postdoctoral work at the University of Wisconsin in Madison (1978 _ 1981), he joined the Central Research and Development Department of E. I. du Pont de Nemours & Company, Wilmington, Delaware, in 1981. Between 1987-91, John served as research supervisor of DuPont's Enzyme Mechanisms Group. From 1991-2005, Dr. Schloss was affiliated with the Department of Medicinal Chemistry, University of Kansas in Lawrence, initially as chair (1991-94) and then professor (1991-2000) and adjunct professor (2000-05). Between 2000-03, he helped to build a new pharmacy program as part of Kuwait University's Health Sciences Center and served as chair of Pharmaceutical Chemistry. In 2002, John helped to found ThioPharma, Inc., in San Diego, which licensed its drug delivery technology to Cenomed Biosciences in 2007. While helping to establish ThioPharma, John also conducted pharmaceutics research at NeuroSystec Corporation in Valencia, California, 2004-08.
Research experience
Summary
More
than 30 years of experience divided between academics and industry:
discovery and development of new drugs and drug-delivery systems; issued
patents covering composition of matter and use; managerial experience
in academics and industry (five times as Chair, Research Supervisor,
Director, and Chief Executive Officer); PI on competitive research
awards from NIH, Office of Naval Research, Maine Technology Institute,
and the Pfeiffer Research Foundation; obtained funding for, built, and
managed core facilities for protein sequencing and amino acid analysis,
large-scale fermentation and protein purification; and mass
spectrometry.
Specialties: Enzyme mechanisms and biochemistry, pharmaceutical chemistry, and analytical chemistry
Specialties: Enzyme mechanisms and biochemistry, pharmaceutical chemistry, and analytical chemistry
Experience
Researcher
Marshall University Research Corporation
Investigating
the regulation of hydrogen sulfide signaling by the taurine
biosynthetic pathway. Support for this project is provided by the U.S.
Army through a CDMRP Discovery Award mechanism.
Professor and Chair, Pharmaceutical Science and Research, School of Pharmacy
Marshall University
Started
the basic science and research effort for a new school of pharmacy.
This was the third new pharmacy program and the 4th pharmacy school that
I had been associated with.
Professor and Chair
University of New England
Built
the basic and clinical science component of a new college of pharmacy;
PI on $4.5 million in competitive funding from the Maine Technology
Institute and an award from the Gustavus & Louise Pfeiffer Research
Foundation
- (Open)1 recommendation
Bryon Crowder
Founder | Wave Creator at Life Is Fluid (LIF)
John was an invaluable resource to Life Is Fluid while at UNE. John and his team were instrumental in initial research and development and I was very impressed with the breadth of his expertise. John was always available and made the time to make...View
CEO, CSO
ThioPharma
Discovery-stage
pharmaceutical company; became virtual in 2003; licensed technology to
Cenomed Biosciences in 2007; concurrently worked as Director of
Chemistry for NeuroSystec (2004-2008); PI on two SBIR grants from NIH,
one from NIAAA and one from NIDCD, maintained funding from the Office of
Naval Research through the University of Kansas
Professor, Medicinal Chemistry
University of Kansas, College of Pharmacy
Served
as Chair (1991-1994) during the transition of the College of Pharmacy
from a B. Pharm. to a Pharm. D. program; discovered a new class of
neuroprotective drugs; helped to build a new pharmacy school in Kuwait
as Chair of Pharmaceutical Chemistry (2000-2003), while maintaining and
renewing research support from the Office of Naval Research through the
University of Kansas; maintained tie as Adjunct Professor (2000-2005)
while building the pharmacy program in Kuwait and starting ThioPharma in
San Diego; continuously funded by the Office of Naval Research from
1994-2004, R01 funding from NIGMS/NIH, US-investigator on several
US-Israel Science Foundation awards; elected Secretary, Biological
Chemistry Division, American Chemical Society (1997-1999); elected to
co-chair the Gordon Research Conference on Enzymes, Coenzymes &
Metabolic Pathways (1992)
Research Supervisor, Enzyme Mechanisms
Du Pont Central Research
Research
Supervisor, Enzyme Mechanisms Group (1987-1991); determined the enzyme
site-of-action for a new class of biocides discovered by screening;
determined the molecular mechanism of these biocides at the enzyme
level; developed a conceptual paradigm for relative inhibitor potency at
the whole organism level for different enzymes in the same metabolic
pathway; recognized expert on slow-binding enzyme inhibition;
co-chairman and invited speaker in a colloquium on "Slow and
Tight-Binding Inhibitors of Enzymes" at the 12th International Congress
of Biochemistry (1982); successful design of mechanism-based inhibitors
with biological activity; Du Pont Agricultural Products Department,
Research and Development Division Accomplishment Award (1990);
co-organizer and co-director, NATO-ASI Summer School on "Enzymatic and
Model Carboxylation and Reduction Reactions for Carbon Dioxide
Utilization" (1989); co-organizer, Workshop on the Biosysthesis of
Branched Chain Amino Acids, Beer Sheva, Israel (1989); discovered
oxygen-consuming side reactions for three mechanistic classes of
enzymes; administrative responsibility for the protein sequencing
facility; built large scale (300 L) fermentation, and protein
purification facilities (> $ 2 million)
Education
Dr John Schloss named Founding Chair of Pharmaceutical Science & Research
“Marshall University School of Pharmacy is starting
with an impressive infrastructure for teaching and research,” Schloss
said. “This will be the third time I have helped start a new pharmacy
program and the Marshall program has the potential to become a leader in
the area of pharmacy education and pharmaceutical research. It is an
exciting time to be a part of Marshall University.”
After receiving his Ph.D. from the University of Tennessee Graduate
School of Biomedical Sciences, located in the Oak Ridge National
Laboratory, Schloss conducted postdoctoral work in the laboratory of
Prof. W. W. Cleland at the University of Wisconsin-Madison from 1978
until 1981.Following completion of his postdoctoral work, Schloss joined the research and development division of E.I. DuPont de Nemours & Co. in Wilmington, Del., where he held positions as a principal investigator and research supervisor. While at DuPont, Schloss published nearly three dozen papers and presented at more than 60 international and national conferences.
Beginning in 1991, Schloss served as professor and chair of the department of medicinal chemistry in the University of Kansas College of Pharmacy. He maintained his affiliation with the pharmacy program in Kansas until 2005. During this time he helped develop a new pharmacy program as part of the Kuwait Health Sciences Center, while maintaining his research programs at the University of Kansas.
In 2002, Schloss co-founded ThioPharma Inc., a biotech startup company focused on discovery-stage pharmaceuticals. While managing ThioPharma from 2002 to 2008, he served as director of chemistry at NeuroSystec, another biotech startup focused on site specific drug delivery to the inner ear, and was principal investigator on two grants funded by the National Institutes of Health. One of the grants was from the National Institute on Alcohol Abuse and Alcoholism and the other was from the National Institute on Deafness and Other Communication Disorders.
Schloss’ expertise in developing a school of pharmacy was tapped again in 2008, when he joined the University of New England. As a founding faculty member and chair of the department of pharmaceutical sciences, Schloss continued his research activities while developing curriculum, recruiting faculty and teaching.
“Dr. Schloss has an extensive background in both the scholarship and discovery in pharmaceutical sciences and will provide excellent leadership for the department’s development,” Dr. Kevin Yingling, dean of the school of pharmacy, said. “He is a fantastic addition to our team and we are happy to welcome him.”
Schloss has received many honors, as well as several notable research awards and grants, including a DuPont
Agricultural Products Department, Research and Development Division
Accomplishment Award, a Gustavus and Louise Pfeiffer Research Foundation
grant, National Institutes of Health grants, Office of Naval Research
grants, US-Israel Binational Research Foundation grants and Maine
Technology Institute grants. He also has provided substantial service to
his profession through organizational leadership.
////////
